GC
EXAS

Guggenheim Capital’s Exact Sciences EXAS Stock Holding History

Guggenheim Capital’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,376
Closed -$3.29M – 1662
2025
Q4 		$3.29M Sell
32,376
-944
-3% -$75.8K 0.02% 541
2025
Q3 		$1.82M Sell
33,320
-1,098
-3% -$54.9K 0.01% 707
2025
Q2 		$1.83M Sell
34,418
-4,054
-11% -$206K 0.01% 677
2025
Q1 		$1.67M Buy
38,472
+9,675
+34% +$490K 0.02% 692
2024
Q4 		$1.62M Sell
28,797
-4,459
-13% -$277K 0.01% 729
2024
Q3 		$2.27M Sell
33,256
-8,212
-20% -$463K 0.02% 787
2024
Q2 		$1.75M Buy
41,468
+6,013
+17% +$331K 0.01% 861
2024
Q1 		$2.45M Buy
35,455
+2,567
+8% +$162K 0.02% 816
2023
Q4 		$2.43M Sell
32,888
-774
-2% -$50.7K 0.02% 775
2023
Q3 		$2.3M Buy
33,662
+1,587
+5% +$135K 0.02% 760
2023
Q2 		$3.01M Sell
32,075
-7,583
-19% -$592K 0.02% 697
2023
Q1 		$2.69M Sell
39,658
-13,943
-26% -$896K 0.02% 751
2022
Q4 		$2.65M Sell
53,601
-9,000
-14% -$368K 0.02% 746
2022
Q3 		$2.03M Sell
62,601
-12,298
-16% -$507K 0.02% 832
2022
Q2 		$2.95M Buy
74,899
+10,256
+16% +$548K 0.02% 747
2022
Q1 		$4.52M Sell
64,643
-1,535
-2% -$112K 0.03% 689
2021
Q4 		$5.15M Buy
66,178
+6,184
+10% +$546K 0.03% 676
2021
Q3 		$5.73M Buy
59,994
+4,069
+7% +$430K 0.03% 602
2021
Q2 		$6.95M Buy
55,925
+333
+0.6% +$39.7K 0.04% 539
2021
Q1 		$7.33M Buy
55,592
+2,701
+5% +$370K 0.05% 470
2020
Q4 		$7.01M Sell
52,891
-13,080
-20% -$1.58M 0.04% 448
2020
Q3 		$6.72M Sell
65,971
-6,114
-8% -$528K 0.05% 408
2020
Q2 		$6.27M Buy
72,085
+18,300
+34% +$1.46M 0.05% 435
2020
Q1 		$3.12M Sell
53,785
-10,038
-16% -$815K 0.03% 624
2019
Q4 		$5.9M Buy
63,823
+14,554
+30% +$1.28M 0.04% 540
2019
Q3 		$4.45M Sell
49,269
-1,449
-3% -$165K 0.04% 653
2019
Q2 		$5.99M Sell
50,718
-11,109
-18% -$1.12M 0.05% 500
2019
Q1 		$5.36M Sell
61,827
-9,418
-13% -$802K 0.04% 577
2018
Q4 		$4.5M Sell
71,245
-3,197
-4% -$219K 0.04% 627
2018
Q3 		$5.88M Sell
74,442
-4,800
-6% -$313K 0.04% 628
2018
Q2 		$4.74M Sell
79,242
-28,765
-27% -$1.55M 0.03% 758
2018
Q1 		$4.36M Sell
108,007
-154
-0.1% -$7.51K 0.01% 1098
2017
Q4 		$5.68M Sell
108,161
-24,782
-19% -$1.32M 0.01% 967
2017
Q3 		$6.27M Buy
132,943
+4,293
+3% +$173K 0.01% 928
2017
Q2 		$4.55M Sell
128,650
-22,052
-15% -$681K 0.01% 1078
2017
Q1 		$3.56M Sell
150,702
-21,883
-13% -$434K 0.01% 1232
2016
Q4 		$2.31M Buy
172,585
+5,029
+3% +$81.2K 0.01% 1565
2016
Q3 		$3.11M Buy
167,556
+7,254
+5% +$128K 0.01% 1308
2016
Q2 		$1.96M Sell
160,302
-120,083
-43% -$904K 0.01% 1576
2016
Q1 		$1.89M Sell
280,385
-69,355
-20% -$444K 0.01% 1612
2015
Q4 		$3.23M Buy
349,740
+1,497
+0.4% +$13.9K 0.01% 1281
2015
Q3 		$6.26M Buy
348,243
+2,144
+0.6% +$49.2K 0.02% 935
2015
Q2 		$10.3M Buy
346,099
+16,523
+5% +$415K 0.03% 820
2015
Q1 		$7.26M Buy
329,576
+51,810
+19% +$1.31M 0.02% 998
2014
Q4 		$7.62M Buy
277,766
+20,765
+8% +$505K 0.02% 943
2014
Q3 		$4.98M Buy
257,001
+28,548
+12% +$523K 0.01% 1197
2014
Q2 		$3.89M Buy
228,453
+921
+0.4% +$12.7K 0.01% 1344
2014
Q1 		$3.22M Sell
227,532
-5,690
-2% -$76.8K 0.01% 1409
2013
Q4 		$2.73M Sell
233,222
-16,730
-7% -$192K 0.01% 1508
2013
Q3 		$2.95M Buy
249,952
+76,877
+44% +$987K 0.01% 1363
2013
Q2 		$2.41M Buy
+173,075
New +$1.88M 0.01% 1409

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Guggenheim Capital's EXAS Position: Q1 2026 in Review

Guggenheim Capital sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 32,376 shares — an estimated $3.29M sold.

Guggenheim Capital first reported a position in EXAS in Q2 2013 and held it in 51 quarters. The position peaked at $10.3M in Q2 2015. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Guggenheim Capital reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Guggenheim Capital sold 32,376 Exact Sciences shares in Q1 2026, an estimated $3.29M.
  • Guggenheim Capital first reported a position in Exact Sciences in Q2 2013 and held it in 51 quarters.
  • Guggenheim Capital's Exact Sciences position peaked at $10.3M in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.